Authors: WELKER HA WEIDEKAMM E HOUWING N DECHATEL R

Citation: Ha. Welker et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF MIBEFRADIL IN HYPERTENSIVE PATIENTS WITH VARYING DEGREES OF RENAL-INSUFFICIENCY, Pharmacology, 56(6), 1998, pp. 297-307

Authors: WILTSHIRE HR SUTTON BM HEEPS G BETTY AM ANGUS DW HARRIS SR WORTH E WELKER HA

Citation: Hr. Wiltshire et al., METABOLISM OF THE CALCIUM-ANTAGONIST, MIBEFRADIL (POSICOR(TM), RO 40-5967) .3. COMPARATIVE PHARMACOKINETICS OF MIBEFRADIL AND ITS MAJOR METABOLITES IN RAT, MARMOSET, CYNOMOLGUS MONKEY AND MAN, Xenobiotica, 27(6), 1997, pp. 557-571

Authors: REIGNER BG WELKER HA

Citation: Bg. Reigner et Ha. Welker, FACTORS INFLUENCING ELIMINATION AND DISTRIBUTION OF FLEROXACIN - METAANALYSIS OF INDIVIDUAL DATA FROM 10 PHARMACOKINETIC STUDIES, Antimicrobial agents and chemotherapy, 40(3), 1996, pp. 575-580

Authors: BURRI C BALTZ T GIROUD C DOUA F WELKER HA BRUN R

Citation: C. Burri et al., PHARMACOKINETIC PROPERTIES OF THE TRYPANOCIDAL DRUG MELARSOPROL, Chemotherapy, 39(4), 1993, pp. 225-234